i have stated in the past that inflammatory bowl disease is a major medical problem and our great drug should be trialled to combat it asap. We should give it to Gastroenterologists to explore. IPPS is safe and this area is massive. There are many PHD guys and dolls who would be willing to get publications with our great product. If we supply the drug the scientific community would take it from there and trial it and publish results. Outsource our drug now for scientific research and get the accretive value asap instead of waiting for years ahead. Little cost to us but many runs on the board. . it would broaden our reach.
Ann: Trading Halt, page-95
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.035(12.7%) |
Mkt cap ! $108.4M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 31.0¢ | 27.5¢ | $108.9K | 371.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1000 | 30.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 17420 | 5 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |